신생아 호흡 곤란 증후군에서 CurosurfⓇ와 NewfactanⓇ의 치료 효과 비교
Comparison of the Therapeutic Effects of Curosurf® and Newfactan® in Respiratory Distress Syndrome
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose : The aim of this study was to compare the clinical effects of modified porcine (CurosurfⓇ) and bovine (NewfactanⓇ) surfactants in the treatment of neonatal respiratory distress syndrome. Methods : Between April 2004 and December 2006, 65 neonates (birth weight ≤2,500 g and gestational age ≤35 weeks) with neonatal respiratory distress syndrome were treated in our neonatal intensive care unit with surfactant. Thirty-one neonates received CurosurfⓇ and 34 neonates received NewfactanⓇ. The neonates were not enrolled if they had major congenital anomalies or meconium aspiration syndrome. We compared the changes in respiratory parameters after surfactant instillation, the incidences of acute and chronic complications, and the mortality between the two treatment groups. Results : Neonatal and maternal demographic characteristics were not different between the groups. The patterns of change in the respiratory parameters after surfactant instillation were not statistically different between the groups. The incidences of surfactant reinstillation and acute complications, such as pneumothorax, patent ductus arteriosus, pulmonary hemorrhage, and grade 3-4 intraventricular hemorrhage, were not different between the neonates who received CurosurfⓇ and the neonates who received NewfactanⓇ. There were no statistically significant differences in the duration of mechanical ventilation, oxygen therapy, hospitalization, prevalence of bronchopulmonary dysplasia, periventricular leukomalacia, retinopathy of prematurity, necrotizing enterocolitis, and mortality between the groups. Conclusion : In the present comparative study, no significant differences in the clinical effects of CurosurfⓇ and NewfactanⓇ were observed.
Abstract
Purpose : The aim of this study was to compare the clinical effects of modified porcine (CurosurfⓇ) and bovine (NewfactanⓇ) surfactants in the treatment of neonatal respiratory distress syndrome. Methods : Between April 2004 and December 2006, 65 neonates (birth weight ≤2,500 g and gestational age ≤35 weeks) with neonatal respiratory distress syndrome were treated in our neonatal intensive care unit with surfactant. Thirty-one neonates received CurosurfⓇ and 34 neonates received NewfactanⓇ. The neonates were not enrolled if they had major congenital anomalies or meconium aspiration syndrome. We compared the changes in respiratory parameters after surfactant instillation, the incidences of acute and chronic complications, and the mortality between the two treatment groups. Results : Neonatal and maternal demographic characteristics were not different between the groups. The patterns of change in the respiratory parameters after surfactant instillation were not statistically different between the groups. The incidences of surfactant reinstillation and acute complications, such as pneumothorax, patent ductus arteriosus, pulmonary hemorrhage, and grade 3-4 intraventricular hemorrhage, were not different between the neonates who received CurosurfⓇ and the neonates who received NewfactanⓇ. There were no statistically significant differences in the duration of mechanical ventilation, oxygen therapy, hospitalization, prevalence of bronchopulmonary dysplasia, periventricular leukomalacia, retinopathy of prematurity, necrotizing enterocolitis, and mortality between the groups. Conclusion : In the present comparative study, no significant differences in the clinical effects of CurosurfⓇ and NewfactanⓇ were observed.
참고문헌 (24)
- Avery ME, "Surface properties in relation to atelectasis and hyaline membrane disease", AMA J Dis Child, 97, pp.517~523 (1959)
- Jobe AH, "Pulmonary surfactant therapy", N Engl J Med, 328, pp.861~868 (1993)
- Sandberg KL, "Surfactant replacement therapy improves ventilation inhomogeneity in infants with respiratory distress syndrome", Pediatr Pulmonol, 24, pp.337~343 (1997)
- Namgung R, "Exogenous surfactant replacement therapy of hyaline membrane disease in premature infants", Yonsei Med J, 30, pp.355~366 (1989)
- Bae CW, "Surfactant replacement therapy in neonates with respiratory distress syndrome: A collective evaluation of trials from 16 hospitals", J Korean Pediatr Soc, 36, pp.244~265 (1993)
- Lee C, "Physical and biological activity of domestic product of modified bovine lung surfactant", J Korean Pediatr Soc, 40, pp.771~785 (1997)
- Lee C, "Clinical trial of domestically bovine lung surfactant YY-38 in neonatal respiratory distress syndrome", J Korean Pediatr Soc, 42, pp.472~483 (1999)
- Lee JJ, "Comparison of surfacten versus newfacten for the treatment of respiratory distress syndrome", J Korean Soc Neonatol, 7, pp.24~32 (2000)
- Choi CW, "Comparison of clinical efficacy of NewfactanⓇ versus SurfactenⓇ for the treatment of respiratory distress syndrome in the newborn infants", J Korean Med Sci, 20, pp.591~597 (2005)
- Jose AH, "Bronchopulmonary dysplasia", Am J Respir Crit Care Med, 163, pp.1723~1729 (2001)
- Bell EF, "High-volume fluid intake prediposes premature infants to necrotizing enterocolitis", Lancet, 2, pp.90~ (1979)
- Fujiwara T, "Artificial surfactant therapy in hyaline membrane disease", Lancet, 1, pp.55~59 (1980)
- Avery ME, "Surfactant-replacement therapy", N Engl J Med, 324, pp.910~912 (1991)
- Horbar JD, "A multicenter randomized trial comparing two surfactants for the treatmen of neonatal respiratory distress syndrome", J Pediatr, 123, pp.757~766 (1993)
- Halliday HL, "Natural vs. synthetic surfactants in neonatal respiratory distress syndrome", Drugs, 51, pp.226~237 (1996)
- Noack G, "Severe neonatal respiatroy distress syndrome treated with the isolated phospholipid fraction of natural surfactant", Acta Pediatr Scand, 76, pp.697~705 (1987)
- Rollins M, "Comparison of clinical responses to natural and synthetic surfactants", J Perinat Med, 21, pp.341~347 (1993)
- Ramanathan R, "North American Study Group. Arandomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants", Am J Perinatol, 21, pp.109~119 (2004)
- Malloy CA, "A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome", Acta Pediatr, 94, pp.779~784 (2005)
- Proquitte H, "Observational study to compare the clinical efficacy of the natural surfactants Alveofact and Curosurf in the treatment of respiratory distress syndrome in premature infants", Respir Med, 101, pp.169~176 (2007)
- Baorutis G, "Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome", Eur J Pediatr, 162, pp.476~480 (2003)
- Lee DW, "Comparison of physical and biological activities between NewfactanⓇ, Surfacten Ⓡ and ExosurfⓇ", J Korean Soc Neonatol, 13, pp.1~8 (2006)
- Hennes HM, "Surfactant replacement therapy in respiratory distress syndrome. Meta-analysis of clinical trials of singledose surfactant extracts", Am J Dis Child, 145, pp.102~104 (1991)
- Halliday HL, "Clinical experience with exogenous natural surfactant", Dev Pharmacol Ther, 13, pp.173~181 (1989)